Fig. 3: NiV vaccine candidates are protective in pigs following a prime-boost immunisation regimen.
From: Nipah virus vaccines evaluated in pigs as a ‘One Health’ approach to protect public health
Pigs were immunised on day 0 and 21 by intramuscular inoculation of 100 µg NiV sG or NiV mcsF proteins in adjuvant, or 1 × 109 IU ChAdOx1 NiV G. On day 42, all pigs were challenged by oronasal inoculation with 1 × 105 PFU NiVM. A Neutralising antibody titres as assessed by NiVM VNT; B, C Viral loads in nasal and oral swabs detected post-challenge by RT-qPCR, respectively. D, E Level of infectious NiV from nasal and oral swabs detected post-challenge by virus isolation, respectively. F, G Viral loads from tissue samples at 6 days post-challenge detected by RT-qPCR and virus isolation, respectively. Postmortem tissues collected: PSLN prescapular lymph node, RPLN retropharyngeal lymph node, SMLN submandibular lymph node, TBLN tracheobronchial lymph nodes, Olf bulb olfactory bulb, Trig ganglion trigeminal ganglion. Significant differences were determined using two-way ANOVA and signified with the following letter: a—significant difference to unvaccinated; b—significant difference to NiV sG; c—significant difference from ChAdOx1 NiV G; d—significant difference to NiV mcsF. NS not significant.
